Table 1. Median overall survival from brain metastasis diagnosis in relation to presence or absence of tested molecule in the brain lesion.
| Molecule | Positive (+) or negative (−) | Median overall survival (months) |
|---|---|---|
| ER | + | 22 |
| − | 6 | |
| PR | + | 36 |
| − | 11 | |
| HER2 | + | 17 |
| − | 10 | |
| EGFR | + | 18 |
| − | 17.5 | |
| IGF1 | + | 13.5 |
| − | 23 | |
| IGF1R | + | 7.5 |
| − | 26 | |
| TGFβ | + | 13.5 |
| − | 23 | |
| P27kip1 | + | 16 |
| − | 9 | |
| Cyclin D1 | + | 17 |
| − | 6 | |
| VEGFA | + | NA |
| − | 15 | |
| VEGFR2 | + | 15 |
| − | 9 |
Abbreviations: EGFR=epidermal growth factor receptor; ER=oestrogen receptor; IGF1=insulin-like growth factor 1; IGF1R=insulin-like growth factor 1 receptor; NA=not applicable; PR=progesterone receptor; TGFβ=transforming growth factor-β; VEGFA=vascular endothelial growth factor A; VEGFR2=vascular endothelial growth factor receptor 2.